Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Sunrun Inc (RUN) vs Sanofi SA (SNY) Price & Performance

Sunrun IncTrade
Sanofi SATrade

Price performance (Past 24H)

Key statistics

Sunrun Inc vs Sanofi SA — how do they compare? Sunrun Inc trades at $11.5 (market cap $2.73B), while Sanofi SA trades at $44.05 (market cap $104.83B). The key difference: Sanofi SA is far larger — about 38.4× Sunrun Inc's market cap, and Sanofi SA pays a 5.5% dividend while Sunrun Inc pays none. Which is the better fit depends on your goals.

RUNSNY
Market Cap
$2.73B$104.83B
Sector
TechnologyHealth
52-Week High
$21.41$52.34
52-Week Low
$9.07$41.33
Enterprise Value
$16.92B$121.32B
Dividend Yield
5.5%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Sunrun Inc

No Aura AI signal available yet.

Sanofi SA

SNY trades at $43.76, down 2.02% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results pending. Revenue grew to $46.72B in 2025, with net income margin improving to 16.72%. Recent positive developments include FDA approval for Sarclisa's wearable injector and EU approval for Cenrifki in multiple sclerosis.

Outlook remains positive with analyst consensus leaning toward buy/hold, though regulatory scrutiny in the EU presents near-term risk. The stock offers a solid dividend yield with the upcoming $2.42 payment. Valuation metrics like P/E of 19.5 and P/B of 1.27 suggest reasonable pricing relative to peers, supported by robust cash flow from operations of $10.75B.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Sunrun Inc

Sunrun Inc. is one of the largest residential solar, battery storage, and energy services companies in the United States. The company provides solar panel installations, battery backup systems, and energy management solutions to homeowners. Sunrun primarily uses a solar-as-a-service model, offering customers solar leases and power purchase agreements (PPAs), which allow homeowners to adopt solar energy with little to no upfront cost. The company's mission is to create a planet run by the sun.

Read more on RUN

About Sanofi SA

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Read more on SNY